Passa al contenuto
Merck
Tutte le immagini(1)

Documenti fondamentali

Visualizza tutta la documentazione

SML0216

Sigma-Aldrich

Brinzolamide

≥98% (HPLC)

Sinonimo/i:

(5R)-5-Ethylamino-3-(3-methoxypropyl)-2,2-dioxo-2?6,9-dithia-3-azabicyclo[4.3.0]nona-7,10-diene-8-sulfonamide, (R)- 4-(ethylamino)-3,4-dihydro-2-(3-methoxypropyl)-2H-Thieno[3,2-e]-1,2-thiazine-6-sulfonamide 1,1-dioxide, AL 4862

Autenticatiper visualizzare i prezzi riservati alla tua organizzazione & contrattuali
Tutte le immagini(1)

About This Item

Formula empirica (notazione di Hill):
C12H21N3O5S3
Numero CAS:
138890-62-7
Peso molecolare:
383.51
Numero MDL:
MFCD08067749
Codice UNSPSC:
12352200
ID PubChem:
329825236
NACRES:
NA.77

Livello qualitativo

100

Saggio

≥98% (HPLC)

Stato

powder

Condizioni di stoccaggio

desiccated

Colore

white to beige

Solubilità

DMSO: ≥10 mg/mL

Temperatura di conservazione

−20°C

Stringa SMILE

CCN[C@H]1CN(CCCOC)S(=O)(=O)c2sc(cc12)S(N)(=O)=O

InChI

1S/C12H21N3O5S3/c1-3-14-10-8-15(5-4-6-20-2)23(18,19)12-9(10)7-11(21-12)22(13,16)17/h7,10,14H,3-6,8H2,1-2H3,(H2,13,16,17)/t10-/m0/s1
HCRKCZRJWPKOAR-JTQLQIEISA-N

Informazioni sul gene

human ... CA2(760)

Cerchi prodotti simili? Visita Guida al confronto tra prodotti

Categorie correlate

Descrizione generale

Brinzolamide is a small molecular weight compound that has an ability to bind melanin. This drug is used in ocular therapy.

Applicazioni

Brinzolamide has been used as a melanin binding compound or drug in melanin binding assays. It has also been used as a carbonic anhydrase inhibitor (CAI).

Azioni biochim/fisiol

Brinzolamide is a carbonic anhydrase II inhibitor
Brinzolamide is a carbonic anhydrase II inhibitor used to lower intraocular pressure.

Codice della classe di stoccaggio

11 - Combustible Solids

Classe di pericolosità dell'acqua (WGK)

WGK 3

Punto d’infiammabilità (°F)

Not applicable

Punto d’infiammabilità (°C)

Not applicable

Scegli una delle versioni più recenti:

Certificati d'analisi (COA)

Lot/Batch Number
106M4720V
113M4733V
012M4715V

Non trovi la versione di tuo interesse?

Se hai bisogno di una versione specifica, puoi cercare il certificato tramite il numero di lotto.

Cerca un COA

Possiedi già questo prodotto?

I documenti relativi ai prodotti acquistati recentemente sono disponibili nell’Archivio dei documenti.

Visita l’Archivio dei documenti

I clienti hanno visto anche

Slide 1 of 5

1 of 5

p-Toluenesulfonamide reagent grade, 97%

Sigma-Aldrich

105902

p-Toluenesulfonamide

Timolol maleate salt ≥98% (TLC), powder

Sigma-Aldrich

T6394

Timolol maleate salt

Acetazolamide ≥99%, powder

Sigma-Aldrich

A6011

Acetazolamide

Donepezil hydrochloride ≥98% (HPLC)

Sigma-Aldrich

D6821

Donepezil hydrochloride

Sulfanilamide ≥98%

Sigma-Aldrich

S9251

Sulfanilamide

Gemma Caterina Maria Rossi et al.
Expert opinion on pharmacotherapy, 12(5), 685-690 (2011-03-10)
To examine the impact of switching glaucoma patients from timolol 0.5% to brinzolamide 1%/timolol 0.5% fixed combination (Brinz/Tim FC) on quality of life and on ocular surface status; to assess efficacy after the switch. 6-month, multicenter, open-label, prospective, switch study
To Be or Not to Be Protonated: Atomic Details of Human Carbonic Anhydrase-Clinical Drug Complexes by Neutron Crystallography and Simulation.
Kovalevsky A, et al.
Structure, 26(3), 383-390 (2018)
Gemma Caterina Maria Rossi et al.
Expert opinion on pharmacotherapy, 12(16), 2425-2431 (2011-06-18)
To assess ocular surface status and tolerability after switching glaucoma patients from dorzolamide/timolol to brinzolamide/timolol fixed combination (FC). Six-month, multicenter, open-label, prospective study that switched 72 patients from dorzolamide/timolol to brinzolamide/timolol FC. Intraocular pressure (IOP), tear film break-up-time (TF-BUT), fluorescein
John H K Liu et al.
Ophthalmology, 118(10), 1995-2000 (2011-06-17)
A core assumption for the 1-eye therapeutic trial of ocular hypotensive medications is the symmetrical reduction of intraocular pressure (IOP) in paired eyes. This assumption was evaluated for 24-hour IOP reduction in patients who underwent monotherapy or adjunctive therapy. Database
Louis F Dell'osso et al.
Journal of neuro-ophthalmology : the official journal of the North American Neuro-Ophthalmology Society, 31(3), 228-233 (2011-06-29)
Recent advances in infantile nystagmus syndrome (INS) surgery have uncovered the therapeutic importance of proprioception. In this report, we test the hypothesis that the topical carbonic anhydrase inhibitor (CAI) brinzolamide (Azopt) has beneficial effects on measures of nystagmus foveation quality
Visualizza tutti i documenti correlati

Il team dei nostri ricercatori vanta grande esperienza in tutte le aree della ricerca quali Life Science, scienza dei materiali, sintesi chimica, cromatografia, discipline analitiche, ecc..

Contatta l'Assistenza Tecnica.